We are live on ! Find out more
SOCM

SR One Capital Management Portfolio holdings

AUM $915M
1-Year Est. Return 209.71%
This Fund
S&P 500
This Quarter Est. Return
-13.64%
1 Year Est. Return
+209.71%
3 Year Est. Return
+484.66%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$410M
AUM Growth
-$88.7M
Cap. Flow
+$2.32M
Cap. Flow %
0.57%
Top 10 Hldgs %
98.99%
Holding
11
New
–
Increased
2
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ORKA
Oruka Therapeutics
ORKA
+$1.34M
2
KALA icon
KALA BIO
KALA
+$979K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$180M 43.88%
2,346,630
– –
SPRY icon
2
ARS Pharmaceuticals
SPRY
$591M
$42.3M 10.32%
4,012,903
– –
CRSP icon
3
CRISPR Therapeutics
CRSP
$5.23B
$41.3M 10.07%
1,048,951
– –
DSGN icon
4
Design Therapeutics
DSGN
$915M
$40.3M 9.82%
6,526,476
– –
ZBIO
5
Zenas BioPharma
ZBIO
$2.05B
$40.2M 9.81%
4,911,539
– –
MLYS icon
6
Mineralys Therapeutics
MLYS
$2.41B
$24.8M 6.05%
2,016,822
– –
ALMS
7
Alumis Inc
ALMS
$3.23B
$15.4M 3.76%
1,959,896
– –
ORKA
8
Oruka Therapeutics
ORKA
$6.93B
$8.34M 2.03%
430,330
+55,000
+15% +$1.34M
NKTX icon
9
Nkarta
NKTX
$167M
$8.3M 2.02%
3,333,333
– –
ENGN icon
10
enGene Therapeutics
ENGN
$122M
$4.97M 1.21%
747,750
– –
KALA icon
11
KALA BIO
KALA
$16.3M
$4.16M 1.01%
11,979
+3,106
+35% +$979K

Similar funds

PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
SC
Sierra Capital Miami, Florida $918M AUM 8.25% 1-Year Est. Return
SI
Symmetry Investments St Helier, Jersey $913M AUM 30.59% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $913M AUM 11.84% 1-Year Est. Return
SAA
Southeast Asset Advisors Thomasville, Georgia $913M AUM 25.32% 1-Year Est. Return
GC
Greenvale Capital London, United Kingdom $912M AUM 34.2% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
FFL
Flat Footed LLC Wilson, Wyoming $920M AUM 86.47% 1-Year Est. Return

SR One Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, SR One Capital Management held 11 positions worth $410M, down 18% from $499M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Trading was light in Q4 2024: portfolio turnover was 0%. SR One Capital Management opened no new positions and made no exits, leaving the 11-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • SR One Capital Management added most to Oruka Therapeutics in Q4 2024, an estimated $1.34M increase.
  • SR One Capital Management's ten largest holdings make up 99% of its $410M portfolio in Q4 2024.
  • SR One Capital Management opened 0 new positions and closed 0 in Q4 2024.
  • SR One Capital Management's portfolio value fell 18% quarter-over-quarter to $410M.

Based on SR One Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.